by TractManager | Oct 31, 2019 | Emerging Technology Report
Zolgensma (onasemnogene abeparvovec-xioi; formerly AVXS-101) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients < 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor...
by TractManager | Oct 31, 2019 | Health Technology Assessment
Health Problem: Varicose veins are dilated, thickened, elongated, and twisted blood vessels that may appear thread-like or as grape-like clusters under the skin, most often on the legs. They are manifestations of chronic venous insufficiency, a condition characterized...
by TractManager | Oct 31, 2019 | Emerging Technology Report
Zolgensma (onasemnogene abeparvovec-xioi; formerly AVXS-101) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients < 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor...
by TractManager | Oct 30, 2019 | Health Technology Assessment
Health Problem: Head and neck cancer (HNC) accounts for approximately 4% of all cancers in the United States, with an estimated 65,410 new HNC diagnoses during 2019 and an estimated 14,620 deaths from the disease. HNC can have a negative impact on a person’s...
by TractManager | Oct 28, 2019 | Emerging Technology Report
Inebilizumab is an investigational anti-CD19 monoclonal antibody. It was developed in response to the unmet treatment needs of patients with neuromyelitis optica spectrum disorder (NMOSD), a rare and debilitating autoimmune demyelinating disease that primary affects...
Recent Comments